Pharmaceutical Executive: What impact will DTC programs have on prescription drug prices? Chris O’Dell: I’m optimistic that they will have an impact in the long term. In the near term, however, what ...

MJH Life Sciences’ acquisition of BPD Healthcare represents a major expansion of strategic capabilities for MJH across ...

Explore CEO insights on decision-making in manufacturing, focusing on risk management, packaging challenges, and strategies ...

In today’s Pharmaceutical Executive Daily, we cover major leadership changes at Novo Nordisk, Kenvue’s request for the FDA to ...

Novo Nordisk's board changes stem from disagreements with the Novo Nordisk Foundation over board composition and strategic ...

Innovent Biologics and Takeda announced a strategic global collaboration aiming to advance next-generation IO and ADC cancer ...

mRNA-based COVID vaccines significantly improve survival rates in cancer patients undergoing immunotherapy, particularly in ...

The solution lies in flexibility. Sites need to be able to work in whatever formats make sense for them, whether that’s a ...

MJH has grown quickly in recent years, expanding both its reach and scope in the healthcare space. In 2019, the company ...

Many of the biodiversity risks associated with pharmaceutical production occur beyond the direct operational control of pharmaceutical businesses, whic means that addressing them requires a ...

Clinical trial sites face persistent payment delays and complex processes, risking their viability and impacting drug development. Solutions prioritize transparency and flexibility.

Pharmaceutical Executive: What impact will TrumpRx and other DTC programs have on drug availability? Jesse Mendelsohn: To be ...